



Blair, A., Stevenson, L., and Sutherland, A. (2012) Synthesis of the isoquinoline alkaloid, crispine C. *Tetrahedron Letters*, 53 (32). pp. 4084-4086. ISSN 0040-4039

Copyright © 2012 Elsevier Ltd

A copy can be downloaded for personal non-commercial research or study, without prior permission or charge

The content must not be changed in any way or reproduced in any format or medium without the formal permission of the copyright holder(s)

When referring to this work, full bibliographic details must be given

<http://eprints.gla.ac.uk/74396>

Deposited on: 21 January 2013


Graphical Abstract

To create your abstract, type over the instructions in the template box below.
Fonts or abstract dimensions should not be changed or altered.

Synthesis of the isoquinoline alkaloid, crispine C

Adele Blair, Louise Stevenson and Andrew Sutherland

Leave this area blank for abstract info.





Synthesis of the isoquinoline alkaloid, crispine C

Adele Blair, Louise Stevenson and Andrew Sutherland*

WestCHEM, School of Chemistry, The Joseph Black Building, University of Glasgow, Glasgow, UK G12 8QQ.

ARTICLE INFO

Article history:

Received

Received in revised form

Accepted

Available online

ABSTRACT

The first total synthesis of the isoquinoline alkaloid, crispine C is described in seven steps using a Henry reaction and the Pictet-Gams variant of the Bischler-Napieralski reaction to effect the key transformations.

2009 Elsevier Ltd. All rights reserved.


Keywords:

Crispine C

Isoquinoline synthesis

Pictet-Gams cyclisation

Guanylation



Carduus crispus, a Mongolian thistle has long been used in Chinese folk medicine for the treatment of colds, stomach problems and rheumatism. In 2002, pharmacological screening of an extract revealed significant cytotoxicity against some human cancer cell lines.¹ The search for the active compounds led to the discovery of five novel alkaloids, crispine A–E (Figure 1). (+)-Crispine A **1** and crispine B **2** have pyrrolo-[2,1-a]isoquinoline skeletons whereas crispine C **3** and crispine D **4** are isoquinoline alkaloids with guanidinyll side-chains. (+)-Crispine E is a tetrahydroisoquinoline with a guanidine derived propyl side-chain at the C-1 position. On isolation, testing of these compounds against SKOV3, KB and Hela human cancer cell lines showed crispine B **2** to have significant cytotoxic activity.¹


Due to their novel structures and the potential of these compounds as pharmaceutical agents, there has been much interest in their synthesis.^{2–4} Crispine A **1** in particular has been prepared using a variety of methods,² including a lipase-catalysed

kinetic resolution of a C-1 substituted tetrahydroisoquinoline²ⁿ as well as by a stereoselective electrochemical cyanation of a chiral tetrahydroisoquinoline.^{2r} Crispine B **2** has been prepared using a Bischler-Napieralski reaction,³ while (+)-crispine E **5** has been synthesised using asymmetric transfer hydrogenation as the key step.^{4b} To date, there have been no reported syntheses of crispine C **3** or crispine D **4**. Our research group has had a long-standing interest in the synthesis of guanylated natural products and

Figure 1 Structures of crispine A **1**, B **2**, C **3**, D **4** and E **5**.


medicinally active agents using in particular, various protected pyrazole-1-carboxamidines for the efficient incorporation of the guanidine group.⁵ Using this approach in combination with a Pictet-Gams reaction to effect the key step, we now report the first total synthesis of crispine C.

Our strategy for the synthesis of crispine C **3** involved the preparation of a suitably functionalised phenethylamine that would be coupled with 4-aminobutyric acid (Scheme 1). The resulting amide was to be used in a Bischler-Napieralski type reaction to form the isoquinoline ring system and the synthesis would then be completed by the incorporation of the guanidine moiety.



Scheme 1 Synthetic approach for the synthesis of crispine C **3**.


Our first attempt at the synthesis of crispine C **3** involved using 3,4-dimethoxyphenethylamine **6** as a starting material and a Bischler-Napieralski reaction to form a C-1 substituted 3,4-dihydroisoquinoline (Scheme 2). 3,4-Dimethoxyphenethylamine **6** was coupled with Cbz-protected 4-aminobutyric acid⁶ using EDCI as a coupling agent to give the corresponding amide **7** in 89% yield. Amide **7** was then treated with neat phosphorus oxychloride to effect the Bischler-Napieralski reaction^{4b,7} and this gave 3,4-dihydroisoquinoline **8** in 73% yield. The next stage of the reaction sequence required dehydrogenation of **8** to complete the synthesis of the isoquinoline ring system. A number of well-precedented methods were investigated including heating **8** in diphenyl ether at 170 °C in the presence of palladium on carbon,⁸ as well as oxidation of **8** with selenium dioxide⁹ and DDQ.¹⁰ However, all attempts led to decomposition or returned only 3,4-dihydroisoquinoline **8**.



Scheme 2 Reagents and conditions: i. 4-Cbz-aminobutyric acid, EDCI, DMAP, CH₂Cl₂, rt, 89%; ii. POCl₃, Δ, 73%.

While the oxidation of dihydroisoquinolines to give isoquinolines is well known, problems with electron-rich ring systems have been reported.¹¹ These issues have been overcome by using the Pictet-Gams modification of the Bischler-Napieralski reaction.¹² A suitable substrate for this reaction was prepared in three steps from 3,4-dimethoxybenzaldehyde **9** (Scheme 3). Initially, **9** was subjected to a Henry reaction¹³ with nitromethane which gave β-nitro alcohol **10** in 85% yield. Hydrogenation under standard conditions gave β-amino alcohol

11 in quantitative yield and this was then coupled with phthalimido-protected butyric acid¹⁴ using EDCI to give β-amido alcohol **12** in 75% yield.¹⁵ With β-amido alcohol **12** in hand, this was subjected to the key Pictet-Gams reaction using phosphorus oxychloride. Although the reaction does proceed when performed neat, the best yield of 66% for isoquinoline **13** was obtained using toluene as a solvent. The phthalimido-protecting group was then removed using hydrazine. The resulting amine was then coupled with commercially available *N,N'*-bis(*tert*-butoxycarbonyl)-1*H*-pyrazole-1-carboxamide **14** in the presence of Hünig's base which gave guanidine **15** in 82% yield over the two steps.^{5,16} Treatment of **15** with TFA to remove the Boc-protecting groups gave crispine C **3** in 73% yield. The spectroscopic data obtained for our synthetic material was in complete agreement with that reported for the natural product by Zhao and co-workers.¹



Scheme 3 Reagents and conditions: i. CH₃NO₂, 4 Å mol. sieves, DMSO, 85%; ii. H₂, 10% Pd/C, MeOH, 100%; iii. 4-Phth-aminobutyric acid, EDCI, DMAP, CH₂Cl₂, 75%; iv. POCl₃, Δ, toluene, 66%; v. hydrazine hydrate, Δ, EtOH; vi. **14**, EtN(*i*-Pr)₂, MeOH, 82% over two steps; vii. TFA, CH₂Cl₂, 73%.

In summary, the first total synthesis of crispine C is reported in seven steps and 25% overall yield. Although a two-step strategy involving a Bischler-Napieralski reaction followed by oxidation was unable to yield the C-1 substituted electron-rich isoquinoline, a more direct ring-forming process utilising a Pictet-Gams reaction was successful. The flexible approach described here is currently being used to prepare a wide range of isoquinoline ring systems with C-1 substituted guanylated side-

chains. The results of these studies and well as biological evaluation of these novel compounds will be communicated in due course.

Acknowledgments

The authors gratefully acknowledge financial support from the Scottish Funding Council, SINAPSE (studentship to AB), BBSRC (studentship to LS) and the University of Glasgow.

References and notes

- Zhang, Q.; Tu, G.; Zhao Y.; Cheng T. *Tetrahedron* **2002**, *58*, 6795–6798.
- (a) Knolker, H. J.; Agarwal, S. *Tetrahedron Lett.* **2005**, *46*, 1173–1175. (b) Szawka, J.; Zawadzka, A.; Wojtasiewicz, K.; Leniewski, A.; Drabowicz J.; Czarnocki, Z. *Tetrahedron: Asymmetry* **2005**, *16*, 3619–3621. (c) Meyer, N.; Opatz, T. *Eur. J. Org. Chem.* **2006**, 3997–4002. (d) Bailey, K. R.; Ellis, A. J.; Reiss, R.; Snape, T. J.; Turner, N. J. *Chem. Commun.* **2007**, 3640–3642. (e) King, F. D. *Tetrahedron* **2007**, *63*, 2053–2056. (f) Allin, S. M.; Gaskell, S. N.; Towler, J. M. R.; Page, P. C. B.; Saha, B.; McKenzie, M. J.; Martin, W. P. *J. Org. Chem.* **2007**, *72*, 8972–8975. (g) Coldham, I.; Jana, S.; Watson, L.; Martin, M.G. *Org. Biomol. Chem.* **2009**, *7*, 1674–1679. (h) Hou, G.-H.; Xie, J.-H.; Yan, P.-C.; Zhou, Q. L. *J. Am. Chem. Soc.* **2009**, *131*, 1366–1367. (i) Chiou, W.-H.; Lin, G.-H.; Hsu, C.-C.; Chaterpaul, S. J.; Ojima, I. *Org. Lett.* **2009**, *11*, 2659–2662. (j) Amat, M.; Elias, V.; Llor, N.; Subrizi, F.; Molins E.; Bosch, J. *Eur. J. Org. Chem.* **2010**, 4017–4026. (k) Yioti, E. G.; Mati, I. K.; Arvanitidis, A. G.; Massen, Z. S.; Alexandraki, E. S.; Gallos, J. K. *Synthesis* **2011**, 142–146. (l) Miyazaki, M.; Ando, N.; Sugai, K.; Seito, Y.; Fukuoka, H.; Kanemitsu, T.; Nagata, K.; Odanaka, Y.; Nakamura, K. T.; Itoh, T. *J. Org. Chem.* **2011**, *76*, 534–542. (m) Gurram, M.; Gyimothy, B.; Wang, R.; Lam, S. Q.; Ahmed, F.; Herr, R. J. *J. Org. Chem.* **2011**, *76*, 1605–1613. (n) Forró, E.; Schöenstein, L.; Fülöp, F. *Tetrahedron: Asymmetry* **2011**, *22*, 1255–1260. (o) Saha, S.; Reddy, C. V. R.; Patro, B. *Tetrahedron Lett.* **2011**, *52*, 4014–4016. (p) Barker, G.; McGrath, J. L.; Klapars, A.; Stead, D.; Zhou, G.; Campos, K.R.; O'Brien, P. *J. Org. Chem.* **2011**, *76*, 5936–5953. (q) Kawai, N.; Matsuda, M.; Uenishi, J. *Tetrahedron* **2011**, *67*, 8648–8653. (r) Louafi, F.; Moreau, J.; Shahane, S.; Golhen, S.; Roisnel, T.; Sinbandhit, S.; Hurvois, J.-P. *J. Org. Chem.* **2011**, *76*, 9720–9732.
- Yasuhara, T.; Zaima, N.; Hashimoto, S.; Yamazaki, M.; Muraoka, O. *Heterocycles* **2009**, *77*, 1397–1402.
- (a) Kanemitsu, T.; Yamashita, Y.; Nagata, K.; Itoh, T. *Heterocycles* **2007**, *74*, 199–203. (b) Czarnocki, S. J.; Wojtasiewicz, K.; Jozwiak, A. P.; Maurin, J. K.; Czarnocki, Z.; Drabowicz, J. *Tetrahedron* **2008**, *64*, 3176–3182.
- (a) Hamilton, D. J.; Sutherland, A. *Tetrahedron Lett.* **2004**, *45*, 5739–5741. (b) Bischoff, R.; McDonald, N.; Sutherland, A. *Tetrahedron Lett.* **2005**, *46*, 7147–7149. (c) Reid, C. M.; Ebikeme, C.; Barrett, M. P.; Patzewitz, E.-M.; Müller, S.; Robins, D. J.; Sutherland, A. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 5399–5401. (d) Zaed, A. M.; Sutherland, A. *Org. Biomol. Chem.* **2010**, *8*, 4394–4399.
- Blankespoor, R. L.; Lau, A. N. K.; Miller, L. L. *J. Org. Chem.* **1984**, *49*, 4441–4446.
- (a) Bischler, A.; Napieralski, B. *Ber.*, **1893**, *26*, 1903–1908. (b) Ott, H.; Hardtmann, G.; Denzer, M.; Frey, A.; Gogerty, J.; Leslie, G.; Trapold, J. *J. Med. Chem.* **1968**, *11*, 777–787.
- Dyke, S. F.; Sainsbury, M. *Tetrahedron* **1965**, *21*, 1907–1915.
- Bernstein, S.; Littell, R. *J. Am. Chem. Soc.* **1960**, *82*, 1235–1240.
- Ahluwalia, V. K.; Arora, K. K.; *Tetrahedron* **1981**, *37*, 1437–1439.
- (a) Dobrowsky, A.; *Monatsh. Chem.* **1951**, *82*, 140–155. (b) Prudhommeaux, E.; Ernouf, G.; Foussard-Blanpin, O.; Viel, C. *Eur. J. Med. Chem.* **1975**, *10*, 19–28. (c) Walker, K. A.; Boots, M. R.; Stubbins, J. F.; Rogers, M. E.; Davis, C. W. *J. Med. Chem.* **1983**, *26*, 174–181.
- Pictet, A.; Gams, A. *Chem. Ber.* **1909**, *42*, 2943–2952.
- Ott, H.; F. A. *Tetrahedron* **2001**, *57*, 915–945.
- Guénin, E.; Monteil, M.; Bouchemal, N.; Prangé, T.; Lecouvey, M. *Eur. J. Org. Chem.* **2007**, 3380–3391.
- On optimisation of the Pictet-Gams reaction, it was found that the phthalimido-protected butyric acid gave a cleaner reaction and higher yield of the desired isoquinoline rather than the Cbz-protected derivative.
- (a) Bernatowicz, M. S.; Wu, Y.; Matsueda, G. R. *J. Org. Chem.* **1992**, *57*, 2497–2502. (b) Bernatowicz, M. S.; Wu, Y.; Matsueda, G. R. *Tetrahedron Lett.* **1993**, *34*, 3389–3392.

Supplementary Material

Supplementary data associated with this article can be found in the online version, at doi:10.1016/j.tetlet.XXXXXXX.